Introduction
Hematopoiesis in vertebrates is a complex, multi-step process that takes place in specific organs during development. 1 The interplay of both growth and differentiation signals results in coordinated, cell-specific gene expression that ultimately allows a pluripotent cell to acquire the phenotypic changes associated with the formation of mature blood cells. 2 This process involves the hierarchy of proliferation and differentiation of progressively larger groups of cells, beginning from hematopoietic stem cells, progressing to committed progenitor cells and extending to the final, mature cells. 2 Although it appears that the commitment of a multipotent hematopoietic precursor to a specific cell lineage is a random process, the probability of commitment to a given lineage can be modulated, in part, by the action of hematopoietic factors that modulate gene expression. 1 Elucidation of the molecular details of the mechanisms that regulate specific lineage commitment has been aided by targeted gene disruption in mice. Thus, erythroid differentiation is regulated by the transcription factor GATA-1, whose activity is required for the transition from the proerythroblast stage to the mature red blood cell. 3 Similarly, a role for the protooncogene c-myb in hematopoiesis has been established. 4 Both megakaryocyte and erythrocyte lineages are closely linked and may share a common unit progenitor, BFU-E/M. 5 The development of the BFU-E/M is dependent on the action of several cytokines including erythropoetin, interleukin-3 and megakaryocyte growth factor.
The study and identification of the signaling mechanisms involved in cell differentiation has been aided by the availability of cell lines that are capable of self-renewal and differentiation. These latter events have been observed in response to a number of cell activators. 6 Megakaryocytic and erythroid differentiation has been shown to be a property of several established cell lines including K562, HEL and MEG-01 cells. [7] [8] [9] [10] Differentiation of these cell lines can be modulated by treatment with PMA, hemin or butyric acid. 10 Megakaryocytic differentiation of K562 cells induced by PMA mimics, in part, the physiologic process that takes place in the bone marrow in response to a variety of stimuli. 10 This differentiation process is characterized by changes in cell morphology and adhesive properties, cell growth arrest, endomitosis and expression of markers associated with megakaryocytes. [10] [11] [12] [13] [14] [15] The signaling cascade that leads to PMA-induced cell cycle arrest, polyploidy and differentiation of K562 cells has been partially described and the role of PKC in the megakaryocyte differentiation process has been established. 16 Studies carried out with K562 cells revealed that PMA induces the translocation of specific isoforms of protein kinase C (PKC) to particulate fractions (plasma and nuclear membranes) with subsequent reduction in the levels of the ␤11 PKC isoform and an increase in the ␣ PKC isoform. 16 PMA treatment also leads to the induction of transcription factors such as jun/fos 17 and egr-1 18 and of protooncogenes such as c-ski 19 and c-sis.
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Treatment of K562 cells with PMA also leads to the p53-independent expression of the cell cycle inhibitor p21waf1/cip. 20 In addition to the effect on cell growth, the changes associated with the adhesive properties of the K562 cells are also evident upon PMA treatment and are likely due, in part, to changes in the cytoskeleton 14 and in integrin expression. 21, 22 This may be due to enhanced cell surface expression of the integrin gp II b /III a (CD41,CD61) which is often used as a differentiation marker of the megakaryocyte cell lineage. 8 More recently, several reports have demonstrated that the MEK/MAPK pathway plays a crucial role in the modulation of megakaryocyte differentiation downstream from PKC activation. [23] [24] [25] [26] [27] Erythroid differentiation of K562 cells is less well characterized. In vitro, differentiation of K562 cells toward the erythroid lineage can be modulated by an array of agents and/or manipulations. 28 Thus, tyrosine kinase inhibitors, 29 inhibitors of DNA replication 7 or antisense constructs to scl 30 have been shown to enhance erythroid differentiation whereas constitutive c-myb expression inhibits the induction of erythroid differentiation.
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A role for PKC in the E/M switch of K562 cells has been proposed based upon studies carried out using PKC inhibitors. 32 Since modulation of PMA-stimulated megakaryocyte differentiation requires the activity of the MEK/MAPK pathway, we investigated whether the proposed role for PKC in the E/M transition could be regulated by the MAPK pathway. Here, we show that inhibition of the basal level of MAPK activity enhances the erythroid phenotype of K562 cells. In addition, we demonstrate PMA-stimulated, MAPK-independent expression of Pyk2 kinase 33 in these cells. 
Materials and methods

Tissue
Immunoprecipitations and immunoblots
Antibodies directed against Pyk2 (for immunoprecipitations) and phosphorylated tyrosine (clone 4G10) were purchased from Upstate Biotechnologies (Lake Placid, NY, USA) to Crk-L (C-20) and C3G (C19) were from Santa Cruz Biotechnology (Santa Cruz, CA, USA), to paxillin (clone 349), c-Cbl (clone 17) and Pyk2 (for immunoblots) were from Transduction Laboratories (Lexington, KY, USA). mAb directed against active MAPK was from Promega (Madison, WI, USA), mAb against hemoglobin (whole molecule) was from Corex Biochem (San Leandro, CA, USA) and HRP-conjugated goat anti-mouse mAb was purchased from Bio-Rad (Richmond, CA, USA). Lysates were prepared in RIPA 34 or HY buffer. 35 Immunoprecipitations were performed on protein matched (Bio-Rad protein assay) lysates for 3 h at 4°C using Protein A/G PLUS Agarose according to the manufacturer's instructions (Santa Cruz Biotechnology). The beads were washed in lysis buffer, boiled for 5 min in 1% SDS, 50 mM Tris, 20% glycerol and 10% ␤ mercapto-ethanol and the immunocomplex was analyzed by protein electrophoresis on 1.5 mM Tris/Glycine gels (Novex, San Diego, CA, USA). Following electrophoretic transfer to 0.2 nitrocellulose (Protran; Schleicher & Schuell, Keene, NH, USA) blotting and chemiluminescence detection using ECL reagents (Amersham, Arlington Heights, IL, USA) were performed as previously described 35 using Biomax film (Eastman Kodak, Rochester, NY, USA).
Transferrin uptake studies K562 cells were treated for 5 days with the MEK inhibitor, PD098059, or for 30 min, prior to resuspending in cold DMEM containing 0.2% BSA and 125 nM fluorescent Transferrin (BODIPY FL; Molecular Probes, Eugene, OR, USA). Cells were then incubated at 4°C for 1 h followed by warming to 37°C for the time indicated in the figure legends. Cells were washed, fixed in 4% formalin for 20 min at 4°C and prepared on a microscope slide for viewing. The fate of fluorescent transferrin was recorded using a fluorescent inverted microscope equipped with a photographic camera (Zeiss, Oberkochen, Germany). After staining, the cells were photographed as described. 69 
RNA isolation and nuclease protection
RNA was isolated from K562 cells treated with or without PMA (40 nM) using RNAzol (Cinna/Biotec Laboratories, Houston, TX, USA) according to the manufacturer's instructions. Oligonucleotides: A 54mer that protects 42 bases of the human Pyk-2 mRNA was synthesized and gel purified by Oligos Etc (Wilsonville, OR, USA). A 43mer that protects 35 bases of 28S rRNA sequence was supplied by Ambion (Austin, TX, USA). Nuclease protection assays were performed according to the manufacturer's instructions (Ambion). Briefly, 3 pmol of oligonucleotides were end-labeled using T4 polynucleotide kinase (Gibco BRL, Gaithersburg, MD) and a 10-fold molar excess of 32 P (3000 Ci/mmol; NEN, Boston, MA, USA) followed by overnight hybridization at 28°C with 40 g of total RNA. After nuclease digestion, protected RNA fragments were recovered by ethanol precipitation and separated on a 12% acrylamide, 7M urea gel (PAGE 12 Complete; Sigma). The radiolabeled probes were then detected by autoradiography (X-OMAT AR; Kodak).
Flow cytometry
Analysis of cell surface expression of the transferrin receptor was performed as previously described 36 using an anti-CD71 mAb obtained from (PharMingen, San Diego, CA, USA). FITCconjugated goat anti-mouse (Zymed, South San Francisco, CA, USA) secondary antibody was used for detection of bound antibody. For analysis of total cell transferrin receptor, cells were fixed in 0.1 ml 4% paraformaldehyde in PBS, centrifuged at 200 g for 5 min and resuspended in 1 ml of 4% paraformaldehyde in PBS. After two washes in PBS, cells were resuspended in 1 ml 0.1% saponin, 0.05% sodium azide in PBS (SAP buffer). After centrifugation, cells were resuspended in 100 l of SAP buffer and anti-CD71 mAb was added at a final concentration of 1 g/ml. The sample was incubated at 4°C overnight, washed twice in SAP buffer and resuspended in Figure 1 Continued 100 l SAP buffer containing 1 g of FITC-conjugated goat anti-mouse IgG. After 1 h, the cells were washed twice in SAP buffer, resuspended in 1% of paraformaldehyde and analyzed using a Coulter Elite Flowcytometer (Miami, FL, USA).
Results
PMA-stimulated MAPK activation is not required for PMA-induced nuclear phenotype changes of K562 cells
PMA stimulation of K562 cells induces a variety of changes in both the morphology and growth of K562 cells. 8 Both the growth inhibitory effect and megakaryocytic differentiation of K562 cells seen with PMA are mediated by prolonged activation of the MAPK pathway. 23, 25, 27 We wanted to determine whether prolonged activation of MAPK was due to continuous activation of two of its upstream regulators, MEK1 and MEK2, or to modulation of a downstream inactivator such as dual specificity phosphatases. Thus, we preactivated MAPK by incubation of K562 cells with PMA in the absence of the MEK inhibitor, PD098059 37, 38 and followed the rate of disappearance of dual phosphorylated MAPK upon addition of the MEK inhibitor. As shown in Figure 1a , MAPK activation by PMA is mostly due to a continuous activation of MEK1 protein since the levels of activated MAPK fall rather quickly if the MEK activity is blocked by the addition of the specific MEK inhibitor, PD098059. The level of MAPK (ERK2) protein is not changed during the course of the experiment.
Several groups have shown that inhibition of PMA-induced activation of MAPK by the MEK inhibitor modifies PMAinduced growth arrest and expression of CD41 in K562 cells. 24, 25, 27 However, here we show that the formation of PMA-induced polylobulation of the nucleus of K562 cells is not blocked by the MEK inhibitor (Figure 1b) . This result demonstrates that some but not all of the PMA-induced changes in K562 cells are MAPK dependent. We therefore investigated, in more detail, the role of MAPK in some of the specific changes induced by PMA. 
Differentiation-dependent and -independent effects of PMA on signaling complexes present in K562 cells
The action of PMA on the content and expression of tyrosine phosphorylated proteins in the presence or absence of the MEK inhibitor was studied in order to distinguish changes induced by PMA from those associated with megakaryocyte differentiation. K562 cells were differentiated in the presence or absence of the MEK inhibitor and the tyrosine phorphorylation pattern of CrkL-associated proteins was analyzed by immunoprecipitation with anti-CrkL antibodies followed by immunoblot with an anti-phosphotyrosine mAb. We have previously shown that K562 cells contain tyrosine phosphorylated signaling proteins associated with the adapter proteins CrkII and CrkL. 39 As seen in Figure 2a , PMA induces a reduction in the tyrosine content or amount of a CrkLassociated 210 kDa protein and an increase in the tyrosine content or/amount of a CrkL-associated 60 kDa protein. The effect of PMA on the 210 kDa protein is independent of the MAPK pathway while the effect on the 60 kDa protein is dependent on this activity. The behavior of the 210 kDa protein is consistent with that of the Bcr-Abl kinase. 27 The amount of tyrosine phosphorylated Cbl, a known partner of CrkL that is present in K562 cells, 39 remains unchanged (Figure 2b ) although a slight increase in the total amount of c-Cbl protein under the conditions studied is seen (data not shown). The level of CrkL protein (Figure 2c ) is not significantly changed by the culturing conditions although a noticeable change in the tyrosine content of CrkL was observed (Figure 2c ). It has previously been shown that CrkL is constitutively tyrosine phosphorylated in K562 cells. 40, 41 We next analyzed the modulation of the CrkL-C3G 42 complex upon PMA stimulation in the presence or absence of the MEK inhibitor. As depicted in Figure 2c , the amount of CrkL-associated C3G protein is increased upon PMA stimulation, however, this effect is independent of the MAPK pathway. As shown in Figure 2a , there was a CrkL-associated tyrosine phosphorylated protein that could be detected upon PMA stimulation only in the absence of the MEK inhibitor. This protein is likely to be paxillin since CrkL immunoprecipitates contain paxillin only upon PMA stimulation (Figure 2c ). This result suggests that paxillin tyrosine phosphorylation is dramatically increased upon differentiation. Indeed, direct paxillin immunoprecipitation show that its tyrosine phosphorylation level is increased upon differentiation (data not shown). It has previously been shown that members of the CrkL family bind to phosphorylated paxillin. 43 The PMA-mediated events that take place upon stimulation of K562 cells lead to the expression of megakaryocyte markers. 8 Therefore, it was of interest to determine whether the expression of Pyk2, a tyrosine kinase expressed in megakaryocytes, 44, 45 was regulated by PMA. Treatment of K562 cells under conditions that lead to megakaryocyte differentiation results in upregulation of Pyk2 expression (Figure 3a) . This event is also seen in another cell line, HEL, that also undergoes PMA-induced differentiation. 10 Enhanced expression of Pyk2 in response to PMA stimulation is likely due to an increase in the mRNA encoding for this protein as demonstrated by a RNAase protection assay (Figure 3b) . It remains to be determined whether this is due to a transcriptional or post-transcriptional regulation.
The pattern of Pyk2 expression and its tyrosine phosphorylation state, as a function of differentiation, was studied. As shown in Figure 4a , neither PMA induced-expression of Pyk2 nor its tyrosine phosphorylation is blocked by the MEK inhibitor (Figure 4a) . Thus, upregulation is independent of the MAPK pathway. Interstingly, we detected the presence of Pyk2 protein in CrkL immunoprecipitates (Figure 4b ) and its appearance was regulated by inhibition of MEK activity. Since the levels of Pyk2 expression are not regulated by this pathway (Figure 4a) , the association of Pyk2 with CrkL is likely to be indirect. Since it is known that Pyk2 and paxillin form a complex 46 and we have shown that paxillin is found in association with CrkL in a differentiation-dependent manner (Figure 2) , the linkage between CrkL and Pyk2 is likely to be paxillin. This is supported by the observation that the isolated SH2 domain of Crk, a close relative of CrkL, is capable of binding paxillin present in extracts prepared from differentiated, but not undifferentiated, K562 cells. Pyk2 is also present in this Crk-SH2/paxillin complex (Figure 4c) . Its presence correlates with the ability of the isolated Crk-SH2 domain to bind to paxillin.
Inhibition of the basal activity of MEK/MAPK pathway enhances the erythroid phenotype of K562 cells
K562 cells express the Bcr-Abl activated tyrosine kinase that has been linked to activation of the Ras pathway. 47, 48 However, a downstream effector of Ras, MAPK, is not fully activated in these cells (Figure 1) . Indeed, activation of MAPK in response to serum stimulation is minimal when it is compared to PMA-stimulated MAPK activation (Figure 5a ). Not surprisingly, culturing these cells in the presence of the MEK inhibitor does not alter their rate of proliferation (Figure 5b) . However, long-term (5 days) treatment of these cells in the presence of the MEK inhibitor induces the expression of hemoglobin (Figure 6b ) that is comparable to globin expression (Table 1) in contrast to two other cell surface proteins, CD16 which is unchanged upon treatment and, ICAM-1, which is down modulated. The rate of internalization of the ligand occupied receptor is not affected by short-or long-term treatment with the MEK inhibitor ( Figure 7) . Thus, increased accumulation of hemoglobin is not due to an increased rate of uptake of iron-bound transferrin.
Discussion
We have explored the role of the MEK/MAPK signaling pathway in the lineage commitment of K562 cells by the use of a MEK-specific inhibitor PD098059. We analyzed the status of known signaling intermediates associated with the transformed phenotype of K562 cells under conditions that lead to or prevent megakaryocyte differentiation. As seen in the results depicted in Figure 2a -c, PMA-induced differentiation of K562 cells is associated with specific changes in the expression and/or tyrosine phosphorylated content of Bcr-Abl and paxillin. Among the cellular events associated with the tumorigenic potential of K562 cells is the constitutive expression of the activated Bcr-Abl tyrosine kinase. 49 The expression of this fusion gene product is associated with an increase in tyrosine phosphorylated proteins [50] [51] [52] [53] that leads to activation of intracellular signaling pathways such as Ras and PI-3K. 47, 54 As previously described, 27 the downregulation of Bcr-Abl by PMA is independent of the MEK/MAPK pathway since it is not blocked by the MEK inhibitor PD098059. However, increased tyrosine phosphorylation of paxillin is blocked by this inhibitor suggesting that this event is linked to PMA-induced differentiation. It has previously been shown that this inhibitor blocks PMA-induced megakaryocyte differentiation of K562 cells. 25, 27 In addition to the above described changes, an increase in tyrosine phosphorylated CrkL was also detected. Interestingly, the amount of C3G protein associated with CrkL was increased upon PMA treatment as well, however, this increase was not dependent on the activity of the MEK/MAPK pathway. The other known partner of the CrkL-SH2 domain, 39 Cbl, does not undergo any significant change under the conditions analyzed in this study.
Changes in the pattern of phosphotyrosine containing proteins during differentiation of K562 cells have been observed. 50, 55 Since both erythroid and megakaryocyte differentiation of K562 cells are associated with a reduction in the levels of Bcr-Abl kinase activity and reversal of PMA-induced growth arrest of these cells does not require high levels of BcrAbl, 27 the contribution of Bcr-Abl downregulation to K562 cell lineage commitment remains unclear. The morphological changes associated with PMA treatment is K562 cells involves the formation of polylobulated nuclei (Figure 1b) . However, this effect is not mediated by the MEK/MAPK pathway. Thus, polylobulation of the nucleus is not sufficient nor is it required for the expression of CD41, a marker for megakaryocyte differentiation whose expression is dependent on a functional MEK/MAPK pathway. 23, 25, 27 A recent study suggests that polyploidy and functional maturation during megakaryocyte differentiation are two distinct events. 56 The above described results illustrate that specific changes associated with PMA treatment of K562 cells are either dependent, thus differentiation linked, or independent of the MEK/MAPK pathway.
PMA-stimulated differentiation of K562 cells is associated with the expression of several genes. 11, [17] [18] [19] We detected PMA-induced expression of Pyk2 kinase, a protein expressed in megakaryocytes, 45 that was not dependent on the activity of the MEK/MAPK pathway. Since PMA-stimulated differentiation of K562 cells mimics the pathway of natural megakaryocyte precursors, 6 it remains to be detemined whether Pyk2 expression is regulated in a similar fashion in vivo.
In vitro differentiation of K562 cells by treatment with PMA is characterized by increased cell-cell adhesion. In agreement with this observation, we detected an increase in tyrosine Inhibition of MAPK activation enhances erythroid differentiation of K562 cells. K562 cell were incubated with (+) or without (−) PD098059 in the presence (a) or absence (b) of Hemin as described in Materials and methods. At the indicated times, the expression of globin was estimated by immunoblot using an antiglobin antibody.
phosphorylation of paxillin, a protein thought to be phosphorylated by integrin-mediated cell adhesion. 57 We also demonstrated that PMA treatment induces the expression of tyrosine phosphorylated Pyk2 (Figures 3 and 4) , an event thought to be involved in the phosphorylation of paxillin. 58 Given the fact that paxillin phosphorylation was seen only under conditions that lead to differentiation, we favor the hypothesis that it becomes phosphorylated due to the enhanced expression of integrin receptors associated with PMA-induced differentiation. 21 Phosphorylated Pyk2 forms a complex with CrkL in differentiated cells (Figure 4) . However, it appears that the association between Pyk2 and CrkL is indirect and mediated by phosphorylated paxillin. This is supported by the observation that the presence of Pyk2 in CrkL immunoprecipitates or in Crk-SH2 in vitro co-precipitation experiments mirrors the pattern of tyrosine phosphorylated paxillin (Figures 2 and 4) . Tyrosine phosphorylated paxillin is known to be a binding partner for the SH2 domain of CrkL-related proteins, 43, 59 and is also found in a complex with Pyk2. 46 PMA-induced megakaryocytic differentiation of K562 cells is dependent on the activity of the MEK/MAPK pathway. 25, 27 K562 cells were treated in the absence (−) or presence (+) of the MEK inhibitor, PD098059. After 5 days, the cells were collected and one half of the cells were treated with saponin, as described in Materials and methods, to assess for total expression of the transferrin receptor, CD16 and ICAM-1. The remaining cells were analyzed for cell surface expression of the transferrin receptor, CD16 and ICAM-1 as outlined in Materials and methods. Mean fluorescent intensity is reported for each condition.
Figure 7
Transferrin receptor internalization is not regulated by the MAPK pathway. K562 cells were incubated for 4 days in the presence of the MEK inhibitor and then incubated with fluorescein-conjugated transferrin for 1 h at 4°C. After warming the cells to 37°C, the rate of cellbound transferrin internalization was followed at the indicated time-points (a) as described in Materials and methods. In (b), the K562 cells were treated for 30 min before the addition of transferrin and analyzed after 10 min post-transfer to 37°C.
However, the contribution of this pathway to the E/M lineage commitment has not been explored in detail. The MEK/MAPK pathway is not essential for the growth of K562 cells ( Figure  5b ). Indeed, the basal level of MAPK activity in these cells is low and refractory to serum stimulation (Figure 5a ) despite the fact that Bcr-Abl expression is connected to activation of Ras, 47 a known upstream modulator of MEK/MAPK. 60 However, inhibition of the basal level of activity by the MEK inhibitor PD098059, induces significant accumulation of globin, a marker for erythroid differentiation. This effect is similar in magnitude to hemin-induced differentiation. Hemin-induced expression of globin does not require MEK activity since it was not blocked by PD098059 (Figure 6 ). Since we did not detect a significant difference in the rate of transferrin uptake but rather an increase in the number of cell surface transferrin receptors (Table 1) , the enhanced expression of hemoglobin correlates best with enhanced differentiation of these cells toward the erythroid lineage upon inhibition of the MAPK pathway.
A role for the MEK/ERK system in cellular differentiation has been proposed in a number of cell systems [61] [62] [63] as well as in Drosophila development. 64 In mammalian cells, both Raf-1 and ERKs have been implicated in the NGF-dependent differentiation of PC12 cells. 62 Direct demonstration of a role for MEK in the differentiation of PC12 cells has been achieved by the use of both activated and dominate negative forms of MEK or by the use of MEK inhibitor PD098059. 62, 65 Similarly, lineage commitment in T cells requires MAPK activation at a specific developmental stage. 63, 66 More recently, several reports have demonstrated that the MEK/MAPK pathway plays a crucial role in the modulation of megakaryocyte differentiation downstream from PKC activation. [23] [24] [25] 27 The results described above, taken together with a previously published work, 25 support the suggestion that the MEK/MAPK pathway plays a switch role in determining the lineage commitment of K562 cells. The exact molecular steps involved in this process are unknown but undoubtedly involve changes in gene expression 1,2 that either positively or negatively modulate erythroid differentiation. Thus, a role for SCL, 30 GATA-2, 67 c-myb 31 and Ldb1/LMO2 68 transcription regulators has been described. The overall outcome is dictated then by the relative contribution of differentiation promoting and proliferation activities.
